Kaan Kavaklı

Ege University — Turkey

Medicine · Health Sciences

28h-index3.0kcitations163works5.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hemophilia Treatment and Research(103), Blood Coagulation and Thrombosis Mechanisms(34), Platelet Disorders and Treatments(33), Chronic Myeloid Leukemia Treatments(22), Myeloproliferative Neoplasms: Diagnosis and Treatment(17)

Publications163 total

Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to &lt; 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ <scp>PROTECT</scp> Main Study
European Journal Of Haematology·2026
Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to &lt; 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ <scp>PROTECT</scp> Main Study
European Journal Of Haematology·2026Open Access
Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B: Results From a Phase 3 Study
Haemophilia·2025
HTRS2025.P2.64 Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A or B on Fitusiran Antithrombin-Based Dosing Regimen (AT-DR): ATLAS-OLE
Research and Practice in Thrombosis and Haemostasis·2025Open Access
Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial
Journal of Thrombosis and Haemostasis·2025· 2 cited
ASSOCIATION OF ANTITHROMBIN LEVELS WITH EFFICACY OF FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A OR B, WITH AND WITHOUT INHIBITORS: A PREDICTIVE MODELING APPROACH
Hematology Transfusion and Cell Therapy·2025Open Access
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
Blood·2025· 21 citedOpen Access
Comprehensive Analysis of Surgical Interventions for Musculoskeletal Disorders in Patients With Bleeding Disorders: Report From a Subspecialty Unit in a Developing Country
Haemophilia·2025Open Access
Simultaneous total hip and knee arthroplasties in hemophilic arthropathy: series of 5 cases
Acta Orthopaedica et Traumatologica Turcica·2024Open Access
Knee arthrodesis in treatment of haemophilic arthropathy of the knee
Haemophilia·2024Open Access
Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals
Haematologica·2024· 3 citedOpen Access
Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE
Blood·2024Open Access
Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
Blood·2024· 6 citedOpen Access
Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
Blood·2024
Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety
Blood·2024Open Access
Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study
Research and Practice in Thrombosis and Haemostasis·2024Open Access
Retrospective analysis of hemophilia B in Turkey: identifying main characteristics and treatment options
Research and Practice in Thrombosis and Haemostasis·2024Open Access
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B
New England Journal of Medicine·2024· 66 cited
Accuracy and clinical role of digital templating for total knee arthroplasty performed on haemophilic knees
Haemophilia·2024· 1 citedOpen Access
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial
Blood·2024· 33 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Flora Peyvandi(11), Guy Young(10), Bülent Zülfikar(7), Mehran Karimi(6), Jerzy Windyga(6), Tadashi Matsushita(6), Gili Kenet(6), Cecil Ross(5), Johnny Mahlangu(5), Johannes Oldenburg(5), Can Balkan(5), Elena Santagostino(4), M. Cerqueira(4), Christoph Male(4), Bülent Antmen(4), Steven R. Lentz(4), Pantep Angchaisuksiri(4), Pratima Chowdary(4), Víctor Jiménez‐Yuste(4), Sedat Gürkök(4)